ID VMAT1_HUMAN Reviewed; 525 AA. AC P54219; E9PDJ5; Q9BRE4; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1996, sequence version 1. DT 27-MAR-2024, entry version 192. DE RecName: Full=Chromaffin granule amine transporter; DE AltName: Full=Solute carrier family 18 member 1; DE AltName: Full=Vesicular amine transporter 1; DE Short=VAT1; GN Name=SLC18A1; Synonyms=VAT1, VMAT1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION (ISOFORM 1), TRANSPORT RP ACTIVITY (ISOFORM 1), ACTIVITY REGULATION (ISOFORM 1), BIOPHYSICOCHEMICAL RP PROPERTIES (ISOFORM 1), SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Pheochromocytoma; RX PubMed=8643547; DOI=10.1073/pnas.93.10.5166; RA Erickson J.D., Schaefer M.K.-H., Bonner T.I., Eiden L.E., Weihe E.; RT "Distinct pharmacological properties and distribution in neurons and RT endocrine cells of two isoforms of the human vesicular monoamine RT transporter."; RL Proc. Natl. Acad. Sci. U.S.A. 93:5166-5171(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANTS PRO-4 AND RP THR-136. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 445-472 (ISOFORM 2), ALTERNATIVE SPLICING, RP FUNCTION (ISOFORMS 1 AND 2), TRANSPORT ACTIVITY (ISOFORM 1), SUBCELLULAR RP LOCATION (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY (ISOFORMS 1 AND 2). RX PubMed=16326835; DOI=10.1677/jme.1.01875; RA Essand M., Vikman S., Grawe J., Gedda L., Hellberg C., Oberg K., RA Totterman T.H., Giandomenico V.; RT "Identification and characterization of a novel splicing variant of RT vesicular monoamine transporter 1."; RL J. Mol. Endocrinol. 35:489-501(2005). RN [5] RP FUNCTION (ISOFORM 1), TRANSPORT ACTIVITY (ISOFORM 1), TISSUE SPECIFICITY, RP AND VARIANTS PRO-4; ARG-10; SER-84; THR-98; PRO-101; THR-136; LEU-138 AND RP VAL-392. RX PubMed=23337945; DOI=10.1038/mp.2012.193; RA Lohoff F.W., Hodge R., Narasimhan S., Nall A., Ferraro T.N., Mickey B.J., RA Heitzeg M.M., Langenecker S.A., Zubieta J.K., Bogdan R., Nikolova Y.S., RA Drabant E., Hariri A.R., Bevilacqua L., Goldman D., Doyle G.A.; RT "Functional genetic variants in the vesicular monoamine transporter 1 RT modulate emotion processing."; RL Mol. Psychiatry 19:129-139(2014). CC -!- FUNCTION: [Isoform 1]: Electrogenic antiporter that exchanges one CC cationic monoamine with two intravesicular protons across the membrane CC of secretory and synaptic vesicles. Uses the electrochemical proton CC gradient established by the V-type proton-pump ATPase to accumulate CC high concentrations of monoamines inside the vesicles prior to their CC release via exocytosis. Transports catecholamines and indolamines with CC higher affinity for serotonin (PubMed:23337945, PubMed:8643547, CC PubMed:16326835). Regulates the transvesicular monoaminergic gradient CC that determines the quantal size. Mediates presynaptic monoaminergic CC vesicle transport in the amygdala and prefrontal brain regions related CC with emotion processing in response to environmental stimuli CC (PubMed:23337945). {ECO:0000269|PubMed:16326835, CC ECO:0000269|PubMed:23337945, ECO:0000269|PubMed:8643547}. CC -!- FUNCTION: [Isoform 2]: Unable to uptake serotonin. CC {ECO:0000269|PubMed:16326835}. CC -!- CATALYTIC ACTIVITY: [Isoform 1]: CC Reaction=2 H(+)(out) + serotonin(in) = 2 H(+)(in) + serotonin(out); CC Xref=Rhea:RHEA:73743, ChEBI:CHEBI:15378, ChEBI:CHEBI:350546; CC Evidence={ECO:0000269|PubMed:16326835, ECO:0000269|PubMed:23337945, CC ECO:0000269|PubMed:8643547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:73744; CC Evidence={ECO:0000305|PubMed:23337945}; CC -!- CATALYTIC ACTIVITY: [Isoform 1]: CC Reaction=(R)-noradrenaline(in) + 2 H(+)(out) = (R)-noradrenaline(out) + CC 2 H(+)(in); Xref=Rhea:RHEA:73747, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:72587; Evidence={ECO:0000269|PubMed:23337945}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:73748; CC Evidence={ECO:0000305|PubMed:23337945}; CC -!- CATALYTIC ACTIVITY: [Isoform 1]: CC Reaction=dopamine(in) + 2 H(+)(out) = dopamine(out) + 2 H(+)(in); CC Xref=Rhea:RHEA:73739, ChEBI:CHEBI:15378, ChEBI:CHEBI:59905; CC Evidence={ECO:0000269|PubMed:23337945}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:73740; CC Evidence={ECO:0000305|PubMed:23337945}; CC -!- ACTIVITY REGULATION: [Isoform 1]: Strongly inhibited by reserpine. Also CC inhibited to a lesser extent by ketanserin and fenfluramine. Not CC significantly inhibited by tetrabenazine. {ECO:0000269|PubMed:8643547}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: [Isoform 1]: CC Kinetic parameters: CC KM=1.3 uM for serotonin {ECO:0000269|PubMed:8643547}; CC -!- INTERACTION: CC P54219-3; Q6RW13-2: AGTRAP; NbExp=3; IntAct=EBI-17595455, EBI-11522760; CC P54219-3; Q86W74-2: ANKRD46; NbExp=3; IntAct=EBI-17595455, EBI-12109402; CC P54219-3; Q9BQE5: APOL2; NbExp=3; IntAct=EBI-17595455, EBI-4290634; CC P54219-3; Q6PL45-2: BRICD5; NbExp=3; IntAct=EBI-17595455, EBI-12244618; CC P54219-3; O14523: C2CD2L; NbExp=3; IntAct=EBI-17595455, EBI-12822627; CC P54219-3; P13236: CCL4; NbExp=3; IntAct=EBI-17595455, EBI-2873970; CC P54219-3; Q8NHW4: CCL4L2; NbExp=3; IntAct=EBI-17595455, EBI-10271156; CC P54219-3; O95406: CNIH1; NbExp=3; IntAct=EBI-17595455, EBI-12172273; CC P54219-3; P29400-2: COL4A5; NbExp=3; IntAct=EBI-17595455, EBI-12211159; CC P54219-3; O14569: CYB561D2; NbExp=3; IntAct=EBI-17595455, EBI-717654; CC P54219-3; Q92520: FAM3C; NbExp=3; IntAct=EBI-17595455, EBI-2876774; CC P54219-3; Q14802-3: FXYD3; NbExp=3; IntAct=EBI-17595455, EBI-12175685; CC P54219-3; Q8WWP7: GIMAP1; NbExp=3; IntAct=EBI-17595455, EBI-11991950; CC P54219-3; P29033: GJB2; NbExp=3; IntAct=EBI-17595455, EBI-3905204; CC P54219-3; Q8TDV0: GPR151; NbExp=3; IntAct=EBI-17595455, EBI-11955647; CC P54219-3; O43561-2: LAT; NbExp=3; IntAct=EBI-17595455, EBI-8070286; CC P54219-3; Q13021: MALL; NbExp=3; IntAct=EBI-17595455, EBI-750078; CC P54219-3; Q6ZSS7: MFSD6; NbExp=3; IntAct=EBI-17595455, EBI-2858252; CC P54219-3; O43451: MGAM; NbExp=3; IntAct=EBI-17595455, EBI-2829774; CC P54219-3; P30301: MIP; NbExp=3; IntAct=EBI-17595455, EBI-8449636; CC P54219-3; P11836: MS4A1; NbExp=3; IntAct=EBI-17595455, EBI-2808234; CC P54219-3; Q5J8X5: MS4A13; NbExp=3; IntAct=EBI-17595455, EBI-12070086; CC P54219-3; Q99519: NEU1; NbExp=3; IntAct=EBI-17595455, EBI-721517; CC P54219-3; Q8IXM6: NRM; NbExp=3; IntAct=EBI-17595455, EBI-10262547; CC P54219-3; Q6UX06: OLFM4; NbExp=3; IntAct=EBI-17595455, EBI-2804156; CC P54219-3; Q9P0S3: ORMDL1; NbExp=3; IntAct=EBI-17595455, EBI-1054848; CC P54219-3; Q9Y5Y5: PEX16; NbExp=3; IntAct=EBI-17595455, EBI-981985; CC P54219-3; P60201-2: PLP1; NbExp=3; IntAct=EBI-17595455, EBI-12188331; CC P54219-3; Q04941: PLP2; NbExp=3; IntAct=EBI-17595455, EBI-608347; CC P54219-3; Q01453: PMP22; NbExp=3; IntAct=EBI-17595455, EBI-2845982; CC P54219-3; P54315: PNLIPRP1; NbExp=3; IntAct=EBI-17595455, EBI-8652812; CC P54219-3; Q59EV6: PPGB; NbExp=3; IntAct=EBI-17595455, EBI-14210385; CC P54219-3; Q9NS64: RPRM; NbExp=3; IntAct=EBI-17595455, EBI-1052363; CC P54219-3; Q9BRI3: SLC30A2; NbExp=3; IntAct=EBI-17595455, EBI-8644112; CC P54219-3; Q8IWU4: SLC30A8; NbExp=3; IntAct=EBI-17595455, EBI-10262251; CC P54219-3; Q969S0: SLC35B4; NbExp=3; IntAct=EBI-17595455, EBI-10281213; CC P54219-3; Q2M3R5: SLC35G1; NbExp=3; IntAct=EBI-17595455, EBI-13311257; CC P54219-3; Q9NVC3: SLC38A7; NbExp=3; IntAct=EBI-17595455, EBI-10314552; CC P54219-3; Q9NP94: SLC39A2; NbExp=3; IntAct=EBI-17595455, EBI-12898013; CC P54219-3; Q9NRQ5: SMCO4; NbExp=3; IntAct=EBI-17595455, EBI-8640191; CC P54219-3; B2RUZ4: SMIM1; NbExp=3; IntAct=EBI-17595455, EBI-12188413; CC P54219-3; P32856-2: STX2; NbExp=3; IntAct=EBI-17595455, EBI-11956649; CC P54219-3; Q9UNK0: STX8; NbExp=3; IntAct=EBI-17595455, EBI-727240; CC P54219-3; P02786: TFRC; NbExp=3; IntAct=EBI-17595455, EBI-355727; CC P54219-3; A0PK00: TMEM120B; NbExp=3; IntAct=EBI-17595455, EBI-10171534; CC P54219-3; Q5BJH2-2: TMEM128; NbExp=3; IntAct=EBI-17595455, EBI-10694905; CC P54219-3; Q9Y6G1: TMEM14A; NbExp=3; IntAct=EBI-17595455, EBI-2800360; CC P54219-3; Q9NUH8: TMEM14B; NbExp=3; IntAct=EBI-17595455, EBI-8638294; CC P54219-3; Q969S6: TMEM203; NbExp=3; IntAct=EBI-17595455, EBI-12274070; CC P54219-3; A2RU14: TMEM218; NbExp=3; IntAct=EBI-17595455, EBI-10173151; CC P54219-3; Q8WW34-2: TMEM239; NbExp=3; IntAct=EBI-17595455, EBI-11528917; CC P54219-3; Q69YG0: TMEM42; NbExp=3; IntAct=EBI-17595455, EBI-12038591; CC P54219-3; Q9H2L4: TMEM60; NbExp=3; IntAct=EBI-17595455, EBI-2852148; CC P54219-3; Q6PI78: TMEM65; NbExp=3; IntAct=EBI-17595455, EBI-6656213; CC P54219-3; Q8N2M4: TMEM86A; NbExp=3; IntAct=EBI-17595455, EBI-12015604; CC P54219-3; O95183: VAMP5; NbExp=3; IntAct=EBI-17595455, EBI-10191195; CC P54219-3; Q9BSR8: YIPF4; NbExp=3; IntAct=EBI-17595455, EBI-751253; CC P54219-3; Q96EC8: YIPF6; NbExp=3; IntAct=EBI-17595455, EBI-751210; CC -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle membrane CC {ECO:0000269|PubMed:8643547}; Multi-pass membrane protein CC {ECO:0000255}. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle CC membrane {ECO:0000250|UniProtKB:Q8R090}; Multi-pass membrane protein CC {ECO:0000255}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasmic vesicle, secretory CC vesicle membrane {ECO:0000269|PubMed:16326835}; Multi-pass membrane CC protein {ECO:0000255}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:16326835}; Multi-pass membrane protein CC {ECO:0000255}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P54219-1; Sequence=Displayed; CC Name=2; Synonyms=VMAT1delta15; CC IsoId=P54219-2; Sequence=VSP_046305; CC Name=3; CC IsoId=P54219-3; Sequence=VSP_046304; CC -!- TISSUE SPECIFICITY: Expressed primarily in neuroendocrine tissues. CC Highly expressed in chromaffin cells of the adrenal medulla (at protein CC level). Detected in peripheral sympathetic ganglia (at protein level). CC Found in some paracrine cells in stomach and duodenum (at protein CC level) (PubMed:8643547). Expressed in substantia nigra CC (PubMed:23337945). {ECO:0000269|PubMed:23337945, CC ECO:0000269|PubMed:8643547}. CC -!- TISSUE SPECIFICITY: [Isoform 1]: Expressed in gastrointestinal tract. CC {ECO:0000269|PubMed:16326835}. CC -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in gastrointestinal tract. CC {ECO:0000269|PubMed:16326835}. CC -!- SIMILARITY: Belongs to the major facilitator superfamily. Vesicular CC transporter family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U39905; AAC50472.1; -; mRNA. DR EMBL; AC025853; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC006317; AAH06317.1; -; mRNA. DR CCDS; CCDS47814.1; -. [P54219-3] DR CCDS; CCDS47815.1; -. [P54219-2] DR CCDS; CCDS6013.1; -. [P54219-1] DR RefSeq; NP_001129163.1; NM_001135691.2. [P54219-1] DR RefSeq; NP_001135796.1; NM_001142324.1. [P54219-3] DR RefSeq; NP_001135797.1; NM_001142325.1. [P54219-2] DR RefSeq; NP_003044.1; NM_003053.3. [P54219-1] DR RefSeq; XP_011542928.1; XM_011544626.1. [P54219-3] DR RefSeq; XP_011542929.1; XM_011544627.1. DR AlphaFoldDB; P54219; -. DR SMR; P54219; -. DR BioGRID; 112458; 125. DR IntAct; P54219; 104. DR STRING; 9606.ENSP00000387549; -. DR BindingDB; P54219; -. DR ChEMBL; CHEMBL1838; -. DR DrugBank; DB01363; Ephedra sinica root. DR DrugBank; DB01577; Metamfetamine. DR DrugBank; DB01442; MMDA. DR DrugBank; DB00368; Norepinephrine. DR DrugBank; DB00206; Reserpine. DR DrugCentral; P54219; -. DR GuidetoPHARMACOLOGY; 1011; -. DR TCDB; 2.A.1.2.12; the major facilitator superfamily (mfs). DR GlyCosmos; P54219; 3 sites, No reported glycans. DR GlyGen; P54219; 3 sites. DR iPTMnet; P54219; -. DR PhosphoSitePlus; P54219; -. DR BioMuta; SLC18A1; -. DR DMDM; 1722741; -. DR MassIVE; P54219; -. DR PaxDb; 9606-ENSP00000387549; -. DR PeptideAtlas; P54219; -. DR ProteomicsDB; 19679; -. DR ProteomicsDB; 56654; -. [P54219-1] DR Antibodypedia; 1514; 203 antibodies from 32 providers. DR DNASU; 6570; -. DR Ensembl; ENST00000265808.11; ENSP00000265808.7; ENSG00000036565.15. [P54219-3] DR Ensembl; ENST00000276373.10; ENSP00000276373.5; ENSG00000036565.15. [P54219-1] DR Ensembl; ENST00000381608.8; ENSP00000371021.4; ENSG00000036565.15. [P54219-2] DR Ensembl; ENST00000437980.3; ENSP00000413361.1; ENSG00000036565.15. [P54219-2] DR Ensembl; ENST00000440926.3; ENSP00000387549.1; ENSG00000036565.15. [P54219-1] DR Ensembl; ENST00000519026.5; ENSP00000429664.1; ENSG00000036565.15. [P54219-3] DR GeneID; 6570; -. DR KEGG; hsa:6570; -. DR MANE-Select; ENST00000276373.10; ENSP00000276373.5; NM_003053.4; NP_003044.1. DR UCSC; uc003wzm.3; human. [P54219-1] DR AGR; HGNC:10934; -. DR CTD; 6570; -. DR DisGeNET; 6570; -. DR GeneCards; SLC18A1; -. DR HGNC; HGNC:10934; SLC18A1. DR HPA; ENSG00000036565; Tissue enriched (adrenal). DR MIM; 193002; gene. DR neXtProt; NX_P54219; -. DR OpenTargets; ENSG00000036565; -. DR PharmGKB; PA324; -. DR VEuPathDB; HostDB:ENSG00000036565; -. DR eggNOG; KOG3764; Eukaryota. DR GeneTree; ENSGT00940000159352; -. DR HOGENOM; CLU_001265_10_9_1; -. DR InParanoid; P54219; -. DR OMA; FGWCVDR; -. DR OrthoDB; 5388206at2759; -. DR PhylomeDB; P54219; -. DR TreeFam; TF313494; -. DR PathwayCommons; P54219; -. DR Reactome; R-HSA-442660; Na+/Cl- dependent neurotransmitter transporters. DR SignaLink; P54219; -. DR SIGNOR; P54219; -. DR BioGRID-ORCS; 6570; 13 hits in 1157 CRISPR screens. DR ChiTaRS; SLC18A1; human. DR GenomeRNAi; 6570; -. DR Pharos; P54219; Tchem. DR PRO; PR:P54219; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; P54219; Protein. DR Bgee; ENSG00000036565; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 56 other cell types or tissues. DR ExpressionAtlas; P54219; baseline and differential. DR GO; GO:0070083; C:clathrin-sculpted monoamine transport vesicle membrane; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0030667; C:secretory granule membrane; IDA:UniProtKB. DR GO; GO:0030672; C:synaptic vesicle membrane; IBA:GO_Central. DR GO; GO:0043195; C:terminal bouton; IBA:GO_Central. DR GO; GO:0008504; F:monoamine transmembrane transporter activity; TAS:UniProtKB. DR GO; GO:0015311; F:monoamine:proton antiporter activity; IDA:UniProtKB. DR GO; GO:0005335; F:serotonin:sodium:chloride symporter activity; IBA:GO_Central. DR GO; GO:0042910; F:xenobiotic transmembrane transporter activity; IEA:InterPro. DR GO; GO:0015842; P:aminergic neurotransmitter loading into synaptic vesicle; IBA:GO_Central. DR GO; GO:0090494; P:dopamine uptake; IDA:UniProtKB. DR GO; GO:0015844; P:monoamine transport; TAS:UniProtKB. DR GO; GO:0051620; P:norepinephrine uptake; IDA:UniProtKB. DR GO; GO:0051610; P:serotonin uptake; IDA:UniProtKB. DR CDD; cd17384; MFS_SLC18A1_2_VAT1_2; 1. DR Gene3D; 1.20.1250.20; MFS general substrate transporter like domains; 2. DR InterPro; IPR011701; MFS. DR InterPro; IPR020846; MFS_dom. DR InterPro; IPR036259; MFS_trans_sf. DR InterPro; IPR004734; Multidrug-R. DR NCBIfam; TIGR00880; 2_A_01_02; 1. DR PANTHER; PTHR23506; -; 1. DR PANTHER; PTHR23506:SF31; CHROMAFFIN GRANULE AMINE TRANSPORTER; 1. DR Pfam; PF07690; MFS_1; 1. DR SUPFAM; SSF103473; MFS general substrate transporter; 1. DR PROSITE; PS50850; MFS; 1. DR Genevisible; P54219; HS. PE 1: Evidence at protein level; KW Alternative splicing; Cytoplasmic vesicle; Endoplasmic reticulum; KW Glycoprotein; Membrane; Neurotransmitter transport; Reference proteome; KW Synapse; Transmembrane; Transmembrane helix; Transport. FT CHAIN 1..525 FT /note="Chromaffin granule amine transporter" FT /id="PRO_0000127510" FT TOPO_DOM 1..21 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 22..42 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 43..138 FT /note="Lumenal, vesicle" FT /evidence="ECO:0000255" FT TRANSMEM 139..158 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 159..167 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 168..188 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 189..197 FT /note="Lumenal, vesicle" FT /evidence="ECO:0000255" FT TRANSMEM 198..218 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 219..227 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 228..250 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 251..256 FT /note="Lumenal, vesicle" FT /evidence="ECO:0000255" FT TRANSMEM 257..279 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 280..299 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 300..319 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 320..335 FT /note="Lumenal, vesicle" FT /evidence="ECO:0000255" FT TRANSMEM 336..360 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 361..365 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 366..386 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 387..397 FT /note="Lumenal, vesicle" FT /evidence="ECO:0000255" FT TRANSMEM 398..418 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 419..422 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 423..443 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 444..448 FT /note="Lumenal, vesicle" FT /evidence="ECO:0000255" FT TRANSMEM 449..470 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 471..525 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REGION 503..525 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 58 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 87 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 104 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 307..338 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_046304" FT VAR_SEQ 445..525 FT /note="PSTGGAIVKAIGFPWLMVITGVINIVYAPLCYYLRSPPAKEEKLAILSQDCP FT METRMYATQKPTKEFPLGEDSDEEPDHEE -> YSESGLPHGDPDVCNPEAHEGISSGG FT GQ (in isoform 2)" FT /evidence="ECO:0000303|PubMed:16326835" FT /id="VSP_046305" FT VARIANT 4 FT /note="T -> P (in dbSNP:rs2270641)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:23337945" FT /id="VAR_021856" FT VARIANT 10 FT /note="Q -> R (found in a patient with bipolar disorder; FT has no significant effect on monoamine vesicular uptake; FT dbSNP:rs150204882)" FT /evidence="ECO:0000269|PubMed:23337945" FT /id="VAR_087305" FT VARIANT 11 FT /note="R -> Q (in dbSNP:rs17092144)" FT /id="VAR_052002" FT VARIANT 74 FT /note="A -> V (in dbSNP:rs17215815)" FT /id="VAR_024632" FT VARIANT 82 FT /note="F -> C (in dbSNP:rs17215822)" FT /id="VAR_029149" FT VARIANT 84 FT /note="F -> S (found in patients with bipolar disorder; FT increases the vesicular uptake of noradrenaline and FT dopamine; dbSNP:rs17215801)" FT /evidence="ECO:0000269|PubMed:23337945" FT /id="VAR_024633" FT VARIANT 98 FT /note="S -> T (in dbSNP:rs2270637)" FT /evidence="ECO:0000269|PubMed:23337945" FT /id="VAR_020033" FT VARIANT 101 FT /note="A -> P (found in a patient with bipolar disorder; FT decreases the vesicular uptake of noradrenaline, dopamine FT and serotonin; dbSNP:rs17222218)" FT /evidence="ECO:0000269|PubMed:23337945" FT /id="VAR_024634" FT VARIANT 136 FT /note="I -> T (decreases the vesicular uptake of FT noradrenaline, dopamine and serotonin; may predispose FT carriers to a increased cortical response to negative FT stimuli and reduced threat-related amygdala reactivity; FT dbSNP:rs1390938)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:23337945" FT /id="VAR_012065" FT VARIANT 138 FT /note="R -> L (found in patients with bipolar disorder; FT decreases the vesicular uptake of noradrenaline, dopamine FT and serotonin; dbSNP:rs148468662)" FT /evidence="ECO:0000269|PubMed:23337945" FT /id="VAR_087306" FT VARIANT 140 FT /note="G -> R (in dbSNP:rs17215808)" FT /id="VAR_029150" FT VARIANT 164 FT /note="I -> M (in dbSNP:rs17222092)" FT /id="VAR_024635" FT VARIANT 202 FT /note="I -> T (in dbSNP:rs17222120)" FT /id="VAR_029151" FT VARIANT 249 FT /note="V -> I (in dbSNP:rs17215759)" FT /id="VAR_024636" FT VARIANT 392 FT /note="L -> V (decreases the vesicular uptake of FT noradrenaline and dopamine; dbSNP:rs17092104)" FT /evidence="ECO:0000269|PubMed:23337945" FT /id="VAR_024637" SQ SEQUENCE 525 AA; 56257 MW; 041F2959F4F2BFBC CRC64; MLRTILDAPQ RLLKEGRASR QLVLVVVFVA LLLDNMLFTV VVPIVPTFLY DMEFKEVNSS LHLGHAGSSP HALASPAFST IFSFFNNNTV AVEESVPSGI AWMNDTASTI PPPATEAISA HKNNCLQGTG FLEEEITRVG VLFASKAVMQ LLVNPFVGPL TNRIGYHIPM FAGFVIMFLS TVMFAFSGTY TLLFVARTLQ GIGSSFSSVA GLGMLASVYT DDHERGRAMG TALGGLALGL LVGAPFGSVM YEFVGKSAPF LILAFLALLD GALQLCILQP SKVSPESAKG TPLFMLLKDP YILVAAGSIC FANMGVAILE PTLPIWMMQT MCSPKWQLGL AFLPASVSYL IGTNLFGVLA NKMGRWLCSL IGMLVVGTSL LCVPLAHNIF GLIGPNAGLG LAIGMVDSSM MPIMGHLVDL RHTSVYGSVY AIADVAFCMG FAIGPSTGGA IVKAIGFPWL MVITGVINIV YAPLCYYLRS PPAKEEKLAI LSQDCPMETR MYATQKPTKE FPLGEDSDEE PDHEE //